Healthcare >> CEO Interviews >> November 15, 2010
Michael Kishbauch, who joined Achillion Pharmaceuticals, Inc., as President and Chief Executive Officer in July 2004, has had an impressive record of launching and commercializing products over his 25 years of pharmaceutical industry experience. Prior to leading Achillion through its initial public offering in 2006, Mr. Kishbauch founded OraPharma, Inc., an emerging pharmaceutical company focused on oral health. In less than seven years, Mr. Kishbauch and his team completed clinical development and launched OraPharma's lead product, successfully took the company public and ultimately sold the company to Johnson & Johnson in February 2003. Previously, Mr. Kishbauch spent several years as President and COO of MedImmune, Inc., a top-tier biotechnology company focused on infectious disease and cancer. Prior to that, he served as Vice President and Senior Product Marketing Executive for Ciba-Geigy, where he oversaw the launches of two products, which at the time were the two most successful product launches in industry history as measured by first-year sales. Mr. Kishbauch began his career with the Procter & Gamble Co. He received a B.A. in biology from Wesleyan University and an MBA from the Wharton School of the University of Pennsylvania. Profile
TWST: What is Achillion Pharmaceuticals?
Mr. Kishbauch: Achillion Pharmaceuticals (ACHN) is a biopharmaceutical company focused entirely on infectious disease. We were founded in the early part of
